LTA4H Modulators for Neuroinflammation and Cognitive Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cognitive impairment, age-related dementia, motor impairment, neuroinflammation, and neurodegenerative diseases have limited success in preventing and reversing the effects of aging, with existing treatments failing to effectively target the underlying mechanisms of these conditions.
Innovation Solution
Modulation of the LTA4H enzyme through pharmacological intervention using LTA4H modulatory agents, which can inhibit the epoxide hydrolase and/or aminopeptidase activities of the enzyme, administered to subjects to improve cognitive function, reduce neuroinflammation, and promote neurogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for cognitive impairment and neurodegenerative diseases, then treatment is provided, but the treatments fail to effectively target the underlying mechanisms of aging-associated conditions
Solution Approach 1:
The patent extracts and targets the specific enzymatic activity of LTA4H that converts LTA4 to LTB4, separating this specific mechanism from general anti-inflammatory treatments. By using selective LTA4H inhibitors, the treatment specifically addresses the LTB4-mediated neuroinflammation pathway rather than using broad-spectrum anti-inflammatory agents, thereby effectively targeting the underlying mechanism of aging-associated cognitive impairment.
Solution Approach 2:
The patent changes the therapeutic parameter from general anti-inflammatory activity to specific LTA4H enzymatic inhibition. This parameter change allows the treatment to specifically reduce LTB4 levels and address the particular pathway involved in neuroinflammation and cognitive decline associated with aging, improving both effectiveness and mechanism-specific targeting.
2Object-affected harmful factors
If LTA4H is inhibited to reduce LTB4 production, then neuroinflammation is reduced, but the dual catalytic activity of LTA4H (epoxide hydrolase and aminopeptidase) must be considered
Solution Approach 1:
The patent applies local quality by selectively inhibiting the epoxide hydrolase active site of LTA4H while potentially preserving or separately managing the aminopeptidase activity. This localized inhibition approach allows specific reduction of LTB4 production and neuroinflammation while considering the enzyme's dual functionality, using structurally selective inhibitors that target particular catalytic regions.
Solution Approach 2:
The patent segments the treatment approach by addressing each catalytic activity of LTA4H separately. The epoxide hydrolase activity is targeted with selective inhibitors to reduce LTB4 and neuroinflammation, while the aminopeptidase activity is considered as a separate functional element that may require distinct management, thus simplifying the complex dual-function enzyme problem into manageable components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modulation of the LTA4H enzyme leads to improved cognitive function, reduced neuroinflammation, and potential reversal of aging-associated symptoms or diseases, providing a new therapeutic approach for treating and preventing cognitive and motor impairments.
Implementation Method 1
LTA4H modulatory agents, which can inhibit the epoxide hydrolase and/or aminopeptidase activities of the enzyme
Implementation Method 2
LTA4H modulatory agents, which can inhibit the epoxide hydrolase and/or aminopeptidase activities of the enzyme
Data Source
AI summary
Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.